Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513888 | 1.00 | HTR6 (0.41) | HTR6QRFPRDRD2DRD3HTR1D | |
| SCHEMBL4519658 | 0.90 | HTR6 (0.52) | HTR6QRFPRTP53MEN1ALOX15 | |
| SCHEMBL4965151 | 0.85 | TP53 (0.41) | HTR6QRFPRTP53IDH1TGFBR1 | |
| SCHEMBL4504796 | 0.85 | TP53 (0.41) | HTR6QRFPRTP53IDH1TGFBR1 | |
| SCHEMBL4530432 | 0.81 | HTR6 (0.51) | HTR6QRFPRIDH1MEN1KMT2A | |
| SCHEMBL4508915 | 0.80 | TP53 (0.43) | HTR6TP53IDH1MEN1KMT2A | |
| SCHEMBL4518652 | 0.73 | HTR6 (0.50) | HTR6QRFPRDRD2DRD3HTR1D | |
| SCHEMBL4519388 | 0.73 | ADRA1A (0.51) | HTR6QRFPRMEN1ALOX15MAPK1 | |
| SCHEMBL4519467 | 0.72 | MEN1 (0.49) | HTR6QRFPRDRD2DRD3MEN1 | |
| SCHEMBL13889126 | 0.71 | ALOX15 (0.42) | HTR6QRFPRIDH1MEN1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-1888518-A1 | NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006126938-A1 | NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | HTR6, HTR1D, HTR1A | HTR6 1/4885QRFPR 79/4885DRD2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.